Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

Journal Articles

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Gurdeep Parmar, Miles Prince, Enrique Ocio, Chatchada Karanes, Sumit Madan, Albert Oriol, Pierre Bories, Michel Delforge, Nashat Gabrail, Dorothee Semiond, Nan Jia, Sandrine Macé, Florence Suzan, Helgi van de Velde, Hang Quach

Blood (2021) 138 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2021-147136

Published: 2021

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137161

Published: 2020

Journal Articles

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139993

Published: 2020

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

Nicole Karras, MD, Ni-Chun Tsai, MS, Ahmed Tahoun, MD, Saloomeh Mokhtari, Haris Ali, MD, Shukaib Arslan, MD, Anna B Pawlowska, MD, Chatchada Karanes, Joseph Rosenthal, MD MS, David S Snyder, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141334

Published: 2020

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Filippo Milano, MD PhD, Andrew R Rezvani, MD, Joanne Kurtzberg, MD, Chatchada Karanes, MD, Jonathan A Gutman, MD, Christine Duncan, MD, Alla Keyzner, MD, Rabi Hanna, MD, Tonya Kimberly Marmon, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 146.

https://doi.org/10.1182/blood-2019-130716

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond, Kenneth Anderson

Blood (2019) 134 (2): 123–133.

https://doi.org/10.1182/blood-2019-02-895193

Published: 2019

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

Monzr Al Malki, MD, Sanjeet Dadwal, MD, Dongyun Yang, PhD, Sally Mokhtari, PhD, Thai Cao, MD, Ketevan Gendzekhadze, David S Snyder, MD, Haris Ali, MD, Ibrahim Aldoss, MD, Amandeep Salhotra, MD, Guido Marcucci, Chatchada Karanes, Pablo Parker, MD, Auayporn P. Nademanee, MDBS, Don Diamond, PhD, John Zaia, MD, Stephen J Forman, Ryotaro Nakamura, MD

Blood (2018) 132 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2018-99-113514

Published: 2018

Journal Articles

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Aaron D Goldberg, MD PhD, Robert H. Collins, MD, Richard M. Stone, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, Carlos E Vigil, MD, Eunice S. Wang, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2018-99-117016

Published: 2018

Journal Articles

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Richard T. Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Chris Storgard, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 2167.

https://doi.org/10.1182/blood-2018-99-115088

Published: 2018

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Journal Articles

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Monzr M. Al Malki, MD, Joo Y. Song, MD, Dongyun Yang, PhD, Thai Cao, MD, Ibrahim Aldoss, MD, Sally Mokhtari, PhD, Sanjeet Dadwal, MD, Ketevan Gendzekhadze, PhD, Anna B Pawlowska, MD, Maryam Ameri, MD, Guido Marcucci, MD, Chatchada Karanes, Pablo Parker, MD, David S. Snyder, MD, David Senitzer, PhD, Auayporn P. Nademanee, MDBS, Stephen J. Forman, MD FACP, Ryotaro Nakamura, MD, Vinod Pullarkat, MD MRCP

Blood (2017) 130 (Supplement 1): 3212.

https://doi.org/10.1182/blood.V130.Suppl_1.3212.3212

Published: 2017

Journal Articles

Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy

Eunice S. Wang, MD, Martin S. Tallman, MD, Richard M. Stone, MD, Roland B. Walter, MD PhD, Chatchada Karanes, MD, Vinay Jain, MBBS, MD, Robert H. Collins, MD

Blood (2017) 130 (Supplement 1): 566.

https://doi.org/10.1182/blood.V130.Suppl_1.566.566

Published: 2017

NARROW

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Immune Mediated Mechanisms of Resistance to Daratumumab

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only